Evidence map›Paper›PMID 29752341›Full record

SynthesisBioscience reports2018

Bingjie Li, Xiaoqing Shi, Yingying Yuan, Mengle Peng, Huifang Jin, Dongchun Qin

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Bioscience reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Journal of Cancer · 2019
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bingjie LiDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Key Laboratory of Laboratory Medicine of Henan Province, Zhengzhou, Henan, China.
Xiaoqing ShiDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Key Laboratory of Laboratory Medicine of Henan Province, Zhengzhou, Henan, China.
Yingying YuanDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Key Laboratory of Laboratory Medicine of Henan Province, Zhengzhou, Henan, China.
Mengle PengDepartment of Clinical Laboratory, The Third People's Hospital of Henan Province, Zhengzhou, Henan, China.
Huifang JinDepartment of Blood Transfusion, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Dongchun QinDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Key Laboratory of Laboratory Medicine of Henan Province, Zhengzhou, Henan, China qindongchunyfy@outlook.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Excision repair cross-complementation group 1 (ERCC1), a DNA repair protein, is vital for maintaining genomic fidelity and integrity. Despite the fact that a mounting body of case-control studies has concentrated on investigating the association of the

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideAsian PeopleBreast NeoplasmsCase-Control StudiesDatabases, GeneticDNA-Binding ProteinsEndonucleasesFemaleGene ExpressionHumansModels, GeneticOdds RatioRisk FactorsDNA-Binding ProteinsEndonucleasesERCC1 protein, humanBreast cancerERCC1Meta-analysisPolymorphismSusceptibility

Identifiers

PMID29752341
PMCPMC6013698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.